<DOC>
	<DOCNO>NCT01943487</DOCNO>
	<brief_summary>This study investigate effect co-administration verapamil steady-state pharmacokinetics ( PK ) solifenacin succinate tamsulosin give combination tablet , EC905 .</brief_summary>
	<brief_title>A Study Evaluate Whether Verapamil Has Effect Uptake Elimination Solifenacin Tamsulosin When Administered Combination Tablet</brief_title>
	<detailed_description>The effect co-administration verapamil steady state PK solifenacin succinate tamsulosin HCl OCAS ( Oral Controlled Absorption System ) evaluate study . Verapamil chosen represent effect moderate CYP3A4 inhibitor combine administration solifenacin tamsulosin give combination tablet EC905 . Subjects admit clinic Day -1 . From Days 1-10 , receive one daily dose EC905 obtain steady state , follow 20 day ( Days 11-30 ) combine dose EC905 verapamil . On Day 10 24-hour PK profile obtain solifenacin/tamsulosin . After last dosing Day 30 , post-dose 24-hour PK profile solifenacin/tamsulosin verapamil obtain . Additionally , vital sign , safety ECG ( Electrocardiogram ) measurement , safety laboratory assessment , adverse event concomitant medication monitor throughout investigational period . Subjects return ESV ( End Study Visit ) 10 day last dosing .</detailed_description>
	<mesh_term>Tamsulosin</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<criteria>Body Mass Index 18.5 30.0 kg/m2 , inclusive Known suspect hypersensitivity EC905 component formulation use Known suspect hypersensitivity verapamil component formulation use Regular use inducer liver metabolism ( e.g . barbiturate , rifampin ) 3 month prior admission Clinical Unit</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Phase I</keyword>
	<keyword>Verapamil</keyword>
	<keyword>Tamsulosin OCAS</keyword>
	<keyword>Solifenacin</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>EC905</keyword>
</DOC>